Marshall Wace
RNAC icon

Marshall Wace’s Cartesian Therapeutics RNAC Stock Holding History

Marshall Wace’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Sell
232,919
-18,196
-7% -$135K ﹤0.01% 1750
2026
Q1 		$1.54M Buy
251,115
+72,975
+41% +$520K ﹤0.01% 1926
2025
Q4 		$1.28M Buy
178,140
+93,334
+110% +$755K ﹤0.01% 1806
2025
Q3 		$867K Buy
84,806
+2,176
+3% +$24.5K ﹤0.01% 2001
2025
Q2 		$859K Buy
82,630
+44,025
+114% +$469K ﹤0.01% 1918
2025
Q1 		$509K Buy
+38,605
New +$690K ﹤0.01% 2072
2024
Q3 		– Sell
-30,038
Closed -$811K – 2892
2024
Q2 		$811K Buy
+30,038
New +$717K ﹤0.01% 1780
2023
Q2 		– Sell
-43,292
Closed -$1.81M – 2908
2023
Q1 		$1.81M Sell
43,292
-389
-0.9% -$18.3K ﹤0.01% 1506
2022
Q4 		$1.48M Sell
43,681
-17,955
-29% -$764K ﹤0.01% 1899
2022
Q3 		$3.03M Buy
61,636
+28,880
+88% +$1.59M 0.01% 1738
2022
Q2 		$1.29M Buy
32,756
+15,780
+93% +$468K ﹤0.01% 2293
2022
Q1 		$627K Sell
16,976
-49,410
-74% -$3.09M ﹤0.01% 2671
2021
Q4 		$6.49M Buy
+66,386
New +$7.14M 0.01% 1176
2021
Q3 		– Sell
-10,143
Closed -$1.27M – 3365
2021
Q2 		$1.27M Buy
+10,143
New +$1.21M 0.01% 1691
2020
Q4 		– Sell
-34,102
Closed -$2.54M – 2128
2020
Q3 		$2.54M Buy
+34,102
New +$2.61M 0.02% 749
2018
Q4 		– Sell
-850
Closed -$396K – 1776
2018
Q3 		$396K Buy
+850
New +$342K ﹤0.01% 972
2016
Q3 		– Sell
-1,207
Closed -$506K – 1109
2016
Q2 		$506K Buy
+1,207
New +$507K ﹤0.01% 824

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's RNAC Position: Q2 2026 in Review

Marshall Wace reduced its Cartesian Therapeutics (RNAC) stake by 7.2% in Q2 2026, selling an estimated $135K and leaving 232,919 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Marshall Wace first reported a position in RNAC in Q2 2016 and has held it in 17 quarters since. The position peaked at $6.49M in Q4 2021. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Marshall Wace held 232,919 shares of Cartesian Therapeutics worth $2.43M as of Q2 2026.
  • Marshall Wace sold 18,196 Cartesian Therapeutics shares in Q2 2026, an estimated $135K.
  • Cartesian Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1750 holding.
  • Marshall Wace first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 17 quarters since.
  • Marshall Wace's Cartesian Therapeutics position peaked at $6.49M in Q4 2021.
  • 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.